Safety profile

Side effects of Retatrutide

In trials, Retatrutide shows a side-effect profile similar to established GLP-1 compounds. The most common adverse effects are gastrointestinal and dose-dependent — most appear during the first weeks of therapy.

Gastrointestinal side effects (common)

Nausea

up to 45%

Most common effect, especially during dose escalation. Usually mild to moderate.

Vomiting

10–20%

Occurs mainly in the first 4–8 weeks, resolves in most patients.

Diarrhea

15–25%

Dose-dependent, typically self-limiting.

Constipation

10–15%

Counterpart to diarrhea, often driven by delayed gastric emptying.

Loss of appetite

expected

Not really an adverse effect — part of the intended action.

Cardiovascular effects

Phase II data showed a mild increase in resting heart rate averaging 5–7 beats per minute — similar to Semaglutide and Tirzepatide. Blood pressure decreased slightly in most trials. Long-term cardiovascular outcome data are still pending.

Rare but relevant risks

Like other incretin mimetics, Retatrutide may theoretically increase risk of pancreatitis, gallstones or — with a corresponding family history — medullary thyroid carcinoma (extrapolated from animal studies with other GLP-1 compounds). These endpoints are systematically captured in the Phase III program.

Contraindications (expected)

Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia type 2 (MEN2)
Pregnancy and breastfeeding
History of acute pancreatitis

Important: All figures come from published Phase I and Phase II data. The final side-effect profile will only be known after completion of the TRIUMPH program and approval. This page does not replace medical advice.

Treatment available